Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

82.42CHF
4:46am EDT
Change (% chg)

CHF-0.06 (-0.07%)
Prev Close
CHF82.48
Open
CHF82.76
Day's High
CHF82.86
Day's Low
CHF82.30
Volume
653,787
Avg. Vol
4,665,360
52-wk High
CHF88.30
52-wk Low
CHF71.84

Summary

Name Age Since Current Position

Joerg Reinhardt

62 2013 Independent Non-Executive Chairman of the Board

Chris Ilsley

2018 President, Chief Executive Officer

Enrico Vanni

67 2013 Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

53 2013 Chief Financial Officer, Member of the Executive Committee

Elizabeth Barrett

56 2018 CEO, Novartis Oncology

Shannon Klinger

2018 Chief Risk and Compliance Officer, Group General Counsel

Steven Baert

44 2014 Head of Human Resources, Member of the Executive Committee

F. Ball

63 2016 Chief Executive Officer of Alcon, Member of the Executive Committee

James Bradner

46 2016 President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee

Richard Francis

50 2014 Chief Executive Officer of Sandoz, Member of the Executive Committee

Paul Hudson

51 2016 Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee

Vasant Narasimhan

2018 Member of the Executive Board

Andre Wyss

51 2016 President of Novartis Operations, Country President for Switzerland, Member of the Executive Committee

Charlotte Pamer-Wieser

2011 Corporate Secretary

Nancy Andrews

60 2015 Non-Executive Independent Director

Dimitri Azar

59 2012 Non-Executive Independent Director

Ton Buechner

53 2016 Non-Executive Independent Director

Srikant Datar

64 2003 Non-Executive Independent Director

Elizabeth Doherty

61 2016 Non-Executive Independent Director

Ann Fudge

66 2008 Non-Executive Independent Director

Pierre Landolt

71 1996 Non-Executive Independent Director

Charles Sawyers

59 2013 Non-Executive Independent Director

Frans van Houten

58 2017 Non-Executive Independent Director

Andreas von Planta

62 2006 Non-Executive Independent Director

William Winters

57 2013 Non-Executive Independent Director

Samir Shah

2013 Global Head Investor Relations

Biographies

Name Description

Joerg Reinhardt

Mr. Joerg Reinhardt, Ph.D., has been Independent Non-Executive Chairman of the Board of Novartis Inc. since August 1, 2013. He is also Chairman of the Research & Development Committee and Chairman of the Board of Trustees of the Novartis Foundation. From 2010 to mid-2013, Mr. Reinhardt was chairman of the board of management and the executive committee of Bayer HealthCare, Germany. Prior to that, he was Chief Operating Officer of Novartis from 2008 to 2010, and Head of the Vaccines and Diagnostics Division of Novartis from 2006 to 2008. Since 2017, Mr. Reinhardt has been a non-executive board member of Swiss Re, Switzerland. Additionally, he was a member of the board of directors of Lonza Group AG in Switzerland from 2012 to 2013, Chairman of the Board of the Genomics Institute of the Novartis Research Foundation in the United States from 2000 to 2010, and a member of the supervisory board of MorphoSys AG in Germany from 2001 to 2004. Mr. Reinhardt graduated with a doctorate in pharmaceutical sciences from Saarland University in Germany. He joined Sandoz Pharma Ltd. in 1982 and held various positions at Sandoz and later Novartis, including Head of Development.

Chris Ilsley

Mr. Chris Ilsley is President, Chief Executive Officer of the Company. Ilsley spent a career driving innovation and entrepreneurship in areas ranging from biotech and cleantech to big data and has previously connected the New England region with the United Kingdom as the Head of Science and Innovation with the office of the British Consulate-General in Boston.

Enrico Vanni

Mr. Enrico Vanni, Ph.D., has been Independent Non-Executive Vice Chairman of the Board at Novartis Inc. since February 22, 2013. He was Member of the Board of Directors at Novartis AG since 2011 till February 22, 2013. He is Chairman of the Compensation Committee. He is also Member of the Audit and Compliance Committee and the Governance, Nomination and Corporate Responsibilities Committee. Mr. Vanni retired as director of McKinsey & Company in 2007. He is a board member of several companies in industries from healthcare to private banking, including Advanced Oncotherapy PLC in the United Kingdom, and non-listed companies such as Lombard Odier SA, Banque Privee BCP (Suisse) SA, and Denzler & Partners SA – all based in Switzerland. He previously served on the boards of Eclosion2 in Switzerland from 2009 to 2017, of Alcon Inc. in Switzerland from 2010 to 2011, and of Actavis PLC in Ireland in 2010. Mr. Vanni holds an engineering degree in chemistry from the Federal Polytechnic School of Lausanne, Switzerland; a doctorate in chemistry from the University of Lausanne; and a Master of Business Administration from INSEAD in Fontainebleau, France. He began his career as a research engineer at the International Business Machines Corp. (IBM) in California, United States, and joined McKinsey in Zurich in 1980. He managed the Geneva office for McKinsey from 1988 to 2004, and consulted for companies in the pharmaceutical, consumer and finance sectors. He led McKinsey’s European pharmaceutical practice and served as a member of the firm’s partner review committee prior to his retirement. From 2008 to 2015, he was an independent consultant, supporting leaders of pharmaceutical and biotechnology companies on core strategic challenges facing the healthcare industry.

Harry Kirsch

Mr. Harry Kirsch has been Chief Financial Officer and Member of the Executive Committee of Novartis Inc. since May 1, 2013. Mr. Kirsch joined Novartis in 2003 and, prior to his current position, served as CFO of the Company’s Pharmaceuticals Division. Under his leadership, the division’s core operating income margin increased, in constant currencies, every quarter of 2011 and 2012 despite patent expirations. At Novartis, he also served as CFO of Pharma Europe, and as Head of Business Planning & Analysis and Financial Operations for the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter & Gamble (P&G) in the United States, where he was CFO of P&G’s global pharmaceutical business. Prior to that, he held finance positions in various categories of P&G’s consumer goods business, technical operations, and Global Business Services organization. Mr. Kirsch represents Novartis on the board of the GSK Consumer Healthcare joint venture. He holds a diploma degree in industrial engineering and economics from the University of Karlsruhe in Germany.

Elizabeth Barrett

Ms. Elizabeth (Liz) Barrett is CEO, Novartis Oncology of the Company since February 1, 2018. She is a member of the Executive Committee of Novartis. Ms. Barrett previously served as global president of oncology at Pfizer Inc. Since joining Pfizer in 2009, she has held other leadership positions, including president of Global Innovative Pharma for Europe, president of the specialty care business unit for North America, and president of United States oncology. Prior to Pfizer, she was vice president and general manager of the oncology business unit at Cephalon Inc. from 2006 to 2009, and before that, she worked at Johnson & Johnson. She started her career at Kraft Foods Group Inc. in 1984. Ms. Barrett holds a Bachelor of Science from the University of Louisiana and a Master of Business Administration from Saint Joseph’s University, both in the US.

Shannon Klinger

Ms. Shannon Thyme Klinger is Chief Risk and Compliance Officer, Group General Counsel of the Company. Shannon Thyme Klinger is currently Chief Ethics, Risk and Compliance Officer. She became Chief Ethics and Compliance Officer and Global Head of Litigation in 2016 and joined the Novartis Executive Committee earlier this year. Ms. Klinger joined Novartis in 2011, as General Counsel, North America, Sandoz US. She was then appointed Global Head Legal and General Counsel for Sandoz. Ms. Klinger holds a JD with Honors from the University of North Carolina at Chapel Hill. Before joining Novartis, Ms. Klinger was a litigation partner at Mayer Brown LLP and Alston & Bird LLP and was Senior Vice President and General Counsel for Solvay Pharmaceuticals Inc.

Steven Baert

Mr. Steven Baert has been Head of Human Resources and Member of the Executive Committee of Novartis Inc. since February 26, 2014. Mr. Baert joined Novartis in 2006 as Head of Human Resources Global Functions in Switzerland. He has held several other senior HR roles, including Head of Human Resources for Emerging Growth Markets, and Global Head, Human Resources, Oncology. Mr. Baert also served as Head of Human Resources, United States and Canada, for Novartis Pharmaceuticals Corporation. Prior to joining Novartis, he held HR positions at Bristol- Myers Squibb Co. and Unilever. Mr. Baert represents Novartis on the board of the GSK Consumer Healthcare joint venture. He holds a Master of Business Administration from the Vlerick Business School in Belgium and a Master of Laws from the Katholieke Universiteit Leuven, also in Belgium. Additionally, he has a Bachelor of Laws from the Katholieke Universiteit Brussels.

F. Ball

Mr. F. Michael (Mike) Ball has been Chief Executive Officer of Alcon and Member of the Executive Committee of Novartis Inc. since February 1, 2016. Mr. Ball previously served as CEO of Hospira Inc. from 2011 to 2015. Prior to that, he held a number of senior leadership positions at Allergan Inc., including president from 2006 to 2011. Before joining Allergan in 1995, Mr. Ball held roles of increasing responsibility in marketing and sales at Syntex Corporation and Eli Lilly & Co. He began his career in the healthcare industry in 1981. Mr. Ball has served on the boards of several companies based in the United States, including Kythera Biopharmaceuticals Inc. (2013 to 2015), Hospira (2011 to 2015), IntraLase Corp. (2005 to 2006), and sTec Inc. (2000 to 2013). He holds a Bachelor of Science and a Master of Business Administration from Queen’s University in Canada.

James Bradner

Mr. James (Jay) Bradner, M.D., has been President of the Novartis Institutes for BioMedical Research (NIBR) and Member of the Executive Committee of Novartis Inc. since March 1, 2016. He joined Novartis in January 2016. Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States from 2005 through 2015. He is a co-founder of five biotechnology companies and has authored more than 180 scientific publications and 30 US patent applications. Dr. Bradner is a graduate of Harvard University and the University of Chicago Medical School in the United States. He completed his residency in medicine at Brigham and Women’s Hospital and his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.

Richard Francis

Mr. Richard D. Francis has been Chief Executive Officer of Sandoz and Member of the Executive Committee at Novartis Inc. since May 1, 2014. Mr. Francis joined Novartis from Biogen Idec, where he held global and country leadership positions during his 13-year career with the company. Most recently, he was senior vice president of the company’s United States commercial organization. From 1998 to 2001, he was at Sanofi in the United Kingdom, and held various marketing roles across the company’s urology, analgesics and cardiovascular products. He also held sales and marketing positions at Lorex Synthelabo and Wyeth. Mr. Francis is a member of the board of directors of Mettler-Toledo International Inc., based in the United States. He received a Bachelor of Arts in economics from Manchester Metropolitan University.

Paul Hudson

Mr. Paul Hudson has been Chief Executive Officer of Novartis Pharmaceuticals and Member of the Executive Committee of Novartis Inc. since July 1, 2016. Mr. Hudson joined Novartis from AstraZeneca PLC, where he most recently was president, AstraZeneca United States and executive vice president, North America. He also served as representative director and president of AstraZeneca K.K. in Japan; as president of AstraZeneca’s business in Spain; and as vice president and primary care director, United Kingdom. Before joining AstraZeneca in 2006, Mr. Hudson held roles of increasing responsibility at Schering-Plough, including leading biologics global marketing. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthelabo UK. Mr. Hudson holds a degree in economics from Manchester Metropolitan University in the UK and a diploma in marketing from the Chartered Institute of Marketing, also in the UK.

Vasant Narasimhan

Dr. Vasant (Vas) Narasimhan, M.D., is Member of the Executive Committee at Novartis Inc. He was Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee of Novartis Inc. from February 1, 2016. Dr. Narasimhan previously was Global Head of Development for Novartis Pharmaceuticals, overseeing the entire general medicines pipeline. He has also served as Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company. Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago. During and after his medical studies, he worked on a range of public health issues in developing countries. He is an elected member of the United States National Academy of Medicine and serves on the board of fellows of Harvard Medical School.

Andre Wyss

Mr. Andre Wyss has been President of Novartis Operations, Country President for Switzerland and Member of the Executive Committee at Novartis Inc. since February 2016. He is responsible for manufacturing, shared services and corporate affairs. Prior to that, he was Member of the Executive Committee, President of Novartis Business Services and Country President for Switzerland at Novartis Inc. from July 1, 2014. Previously, he was Global Head of Novartis Business Services (NBS) since May 1, 2014 till July 1, 2014. Mr. Wyss has been with Novartis since 1984 when he was a chemistry apprentice in manufacturing at Sandoz. Before being appointed President of Novartis Operations, he served as Head of Novartis Business Services, building and implementing a shared services organization across Novartis. Prior to that, he held several other leadership positions, including United States Country Head and President of Novartis Pharmaceuticals Corporation; Head of the Pharmaceuticals Division for the AMAC region (Asia-Pacific, Middle East and African countries); Group Emerging Markets Head; and Country President and Head of Pharmaceuticals, Greece. Mr. Wyss received a graduate degree in economics from the School of Economics and Business Administration (HWV) in Switzerland in 1995. He is a member of the board of economiesuisse.

Charlotte Pamer-Wieser

Ms. Charlotte Pamer-Wieser, Ph.D., has been Corporate Secretary at Novartis Inc. since September 2011. She started her professional career in 2004 as an associate at Walder Wyss Ltd. in Zurich, Switzerland. From 2007 to 2011, she worked as a senior associate at Baer & Karrer Ltd. in Zurich. Her areas of specialization include corporate law, mergers and acquisitions, company reorganizations, and banking and finance law. Ms. Pamer-Wieser holds a doctorate in law from the University of Basel in Switzerland, and a Master of Laws from the University of Chicago Law School in the United States. In 2002, she was admitted to the Basel bar, and from 2007 to 2010, she was a lecturer at the University of Basel. She has written a number of articles on corporate law and is a member of the Association Internationale des Jeunes Avocats.

Nancy Andrews

Dr. Nancy C. Andrews, M.D., Ph.D., has been Non-Executive Independent Director of Novartis Inc. since February 27, 2015. She is a member of the Research & Development Committee and the Risk Committee. Dr. Andrews is dean emerita of the Duke University School of Medicine and vice chancellor emerita for academic affairs at Duke University in the United States. She served as dean and vice chancellor from 2007 to 2017. She is a professor of pediatrics, pharmacology and cancer biology at Duke, and was elected as a fellow of the American Association for the Advancement of Science and to membership in the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. She is chair of the board of directors of the American Academy of Arts and Sciences and of the Burroughs Wellcome Fund, a member of the Massachusetts Institute of Technology (MIT) Corporation, and former president of the American Society for Clinical Investigation. Additionally, she serves on the council of the National Academy of Medicine and on the Scientific Management Review Board of the US National Institutes of Health. Dr. Andrews holds a doctorate in biology from MIT and a doctor of medicine from Harvard Medical School. She completed her residency and fellowship trainings in pediatrics and hematology/oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute, also in the US, and served as an attending physician at Boston Children’s Hospital. Prior to joining Duke, Dr. Andrews was director of the Harvard/MIT M.D.-Ph.D. Program, and dean of basic sciences and graduate studies as well as professor of pediatrics at Harvard Medical School. From 1993 to 2006, she was a biomedical research investigator at the Howard Hughes Medical Institute in the US. Her research expertise is in iron homeostasis and mouse models of human diseases.

Dimitri Azar

Dr. Dimitri Azar, M.D., has been Non-Executive Independent Director of Novartis Inc. since February 2012. He is Member of the Audit and Compliance Committee and the Research & Development Committee. Dr. Azar is senior director of ophthalmological innovation at Verily Life Sciences. He has also served as dean of the University of Illinois at Chicago (UIC) College of Medicine in the United States since 2011, and as professor of ophthalmology, bioengineering and pharmacology at UIC since 2006. From 2006 to 2011, he was head of the Department of Ophthalmology and Visual Sciences at UIC. He is a member of the American Ophthalmological Society, former president of the Chicago Ophthalmological Society, and president-elect of the Chicago Medical Society. Additionally, he is on the board of the Tear Film and Ocular Surface Society, the board of Verb Surgical Inc., and the scientific board of Verily – all based in the United States. Dr. Azar began his career at the American University of Beirut Medical Center in Lebanon, and completed his fellowship and residency training at the Massachusetts Eye and Ear Infirmary at Harvard Medical School. His research on matrix metalloproteinases in corneal wound healing and angiogenesis has been funded by the US National Institutes of Health since 1993. Dr. Azar practiced at the Wilmer Eye Institute at the Johns Hopkins Hospital School of Medicine in the US, and then returned to the Massachusetts Eye and Ear Infirmary as director of cornea and external disease. He became professor of ophthalmology with tenure at Harvard Medical School in 2003. Dr. Azar holds a master’s degree from Harvard and an Executive Master of Business Administration from the University of Chicago Booth School of Business.

Ton Buechner

Mr. Ton Buechner has been Non-Executive Independent Director of Novartis Inc. since February 24, 2016. He is Member of the Risk Committee. Mr. Buechner most recently served as chairman and CEO of the executive board of Dutch multinational Akzo- Nobel from 2012 to 2017. Prior to joining AkzoNobel, he spent almost two decades at the Sulzer Corporation in Switzerland, where he was appointed divisional president in 2001 and served as president and CEO from 2007 to 2011. Mr. Buechner’s early career was spent in the oil and gas construction industry, and included roles at Allseas Engineering in the Netherlands and at Aker Kvaerner in Singapore. He is a member of the supervisory board of Voith GmbH in Germany. Mr. Buechner is an engineer by training. He received his master’s degree in civil engineering from Delft University of Technology in the Netherlands in 1988, specializing in offshore construction technology and coastal engineering. Mr. Buechner holds a Master of Business Administration from IMD business school in Lausanne, Switzerland.

Srikant Datar

Mr. Srikant M. Datar, Ph.D., has been Non-Executive Independent Director of Novartis Inc. since 2003. He is Chairman of the Risk Committee, as well as Member of the Audit and Compliance Committee and the Compensation Committee. The Board of Directors has appointed him as Audit Committee Financial Expert. Since 1996, Mr. Datar has been the Arthur Lowes Dickinson professor of business administration at Harvard Business School in the United States. Additionally, since 2015, he has been faculty chair of the Harvard Innovation Lab and senior associate dean for university affairs at Harvard Business School. He is a member of the boards of directors of ICF International Inc., Stryker Corp. and T-Mobile US. He previously served on the boards of HCL Technologies Ltd. (2012 to 2014) and KPIT Cummins Infosystems Ltd (2007 to 2012), both based in India. Mr. Datar graduated in 1973 with distinction in mathematics and economics from the University of Bombay in India. He is a chartered accountant, and holds two master’s degrees and a doctorate from Stanford University. Mr. Datar has worked as an accountant and planner in industry, and as a professor at Carnegie Mellon University, Stanford University and Harvard University, all in the US. His research interests are in the areas of cost management, measurement of productivity, new product development, innovation, time-based competition, incentives and performance evaluation. He is the author of many scientific publications and has received several academic awards and honors. Mr. Datar has also advised and worked with numerous companies in research, development and training.

Elizabeth Doherty

Ms. Elizabeth (Liz) Doherty has been Non-Executive Independent Director of Novartis Inc. since February 24, 2016. She is Chairman of the Audit and Compliance Committee and a member of the Risk Committee. The Board of Directors has appointed her as Audit Committee Financial Expert. Ms. Doherty is a non-executive director and chairman of the audit committee of Dunelm Group PLC in the United Kingdom, and a member of the supervisory board and audit committee of Corbion NV in the Netherlands. She is a fellow of the Chartered Institute of Management Accountants; a non-executive board member of the UK Ministry of Justice; a non-executive board member of Her Majesty’s Courts and Tribunals Service in the UK; and an advisor to GBfoods and Affinity Petcare SA, subsidiaries of Agrolimen SA. She previously served as a non-executive director and audit committee member at Delhaize Group in Belgium and Nokia Corp. in Finland, and as a non-executive director at SABMiller PLC in the UK. Ms. Doherty received her bachelor’s degree in liberal studies in science (physics) from the University of Manchester. She began her career as an auditor and has held senior finance and accounting roles at Unilever PLC and Tesco PLC. Her previous positions also include interim chief financial officer (CFO) of Cognita Schools Ltd. from 2014 to 2015, CFO and board member of Reckitt Benckiser Group PLC from 2011 to 2013, interim CFO of City Inn in 2010, and CFO of Brambles Ltd. from 2007 to 2009.

Ann Fudge

Ms. Ann Marie Fudge has been Non-Executive Independent Director at Novartis Inc. since February 26, 2008. She is Member of the Risk Committee; the Compensation Committee; and the Governance, Nomination and Corporate Responsibilities Committee. Ms. Fudge is vice chairman and senior independent director of Unilever NV, London and Rotterdam. She is also chair of the United States Program Advisory Panel of the Bill & Melinda Gates Foundation; a director of Northrop Grumman Corporation in the United States; a trustee of Boston-based WGBH public media; and a member of the visiting committee of Harvard Business School in the United States. She served on the board of General Electric Co. from 1999 to 2015. Ms. Fudge received her bachelor’s degree from Simmons College and her Master of Business Administration from Harvard Business School. She is former chairman and CEO of Young & Rubicam Brands, New York. Before that, she served as president of the Beverages, Desserts and Post Division of Kraft Foods Inc.

Pierre Landolt

Mr. Pierre Landolt, Ph.D., has been Non-Executive Independent Director at Novartis Inc. since 1996. He is Member of the Governance, Nomination and Corporate Responsibilities Committee. Mr. Landolt is chairman of the Sandoz Family Foundation, overseeing its development in several investment fields. He is also chairman of the Swiss private bank Landolt & Cie SA. In Switzerland, he is chairman of Emasan AG and Vaucher Manufacture Fleurier SA, and vice chairman of Parmigiani Fleurier SA. Additionally, he is vice chairman of the Montreux Jazz Festival Foundation and a board member of Amazentis SA, Switzerland, and the Eneas Fund, Cayman Islands. In Brazil, Mr. Landolt is president of AxialPar Ltda. and Moco Agropecuaria Ltda., the Instituto Fazenda Tamandua and the Instituto Estrela de Fomento ao Microcredito. Mr. Landolt graduated with a bachelor’s degree in law from the University of Paris-Assas. From 1974 to 1976, he worked for Sandoz Brazil. In 1977, he acquired an agricultural estate in the semi-arid Northeast Region of Brazil, and within several years he converted it into a model farm in organic and biodynamic production. Since 1997, Mr. Landolt has been associate and chairman of AxialPar Ltda., Brazil, an investment company focused on sustainable development. In 2007, he co-founded Amazentis SA, a startup company active in the convergence space of medication and nutrition. In 2011, Mr. Landolt received the title of Docteur des Sciences Economiques Honoris Causa from the University of Lausanne in Switzerland.

Charles Sawyers

Dr. Charles L. Sawyers, M.D., has been Non-Executive Independent Director of Novartis Inc. since 2013. He is Member of the Research & Development Committee and the Governance, Nomination and Corporate Responsibilities Committee. In the United States, Dr. Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, professor of medicine and of cell and developmental biology at the Weill Cornell Graduate School of Medical Sciences, and an investigator at the Howard Hughes Medical Institute. He was appointed to the United States National Cancer Advisory Board, and is former president of the American Association for Cancer Research and of the American Society for Clinical Investigation. He is also a member of the United States National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He serves as a science advisor for the following companies: Agios Pharmaceuticals Inc., Housey Pharmaceutical Research Laboratories, Nextech Invest Ltd., Blueprint Medicines Corporation, BeiGene Ltd., The Column Group, ORIC Pharmaceuticals Inc., KSQ Therapeutics Inc., Foghorn Therapeutics Inc., and PMV Pharmaceuticals Inc. Dr. Sawyers received his doctor of medicine from the Johns Hopkins University School of Medicine and worked at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, for nearly 18 years before joining Memorial Sloan Kettering in 2006. An internationally acclaimed cancer researcher, he co-developed the Novartis cancer drug Gleevec/Glivec and has received numerous honors and awards, including the Lasker-DeBakey Clinical Medical Research Award in 2009.

Frans van Houten

Mr. Frans van Houten has been Non-Executive Independent Director at Novartis Inc. since February 28, 2017. Mr. van Houten is CEO and chairman of the executive committee and the board of management of Royal Philips, a position he has held since 2011. Under his leadership, Philips has transformed itself into a focused health technology company. In May 2016, he also became vice chairman and a member of the supervisory board of Philips Lighting. Mr. van Houten holds a master’s degree in economics and business management from Erasmus University in Rotterdam, the Netherlands. He joined Philips in 1986 and has held multiple global senior leadership positions. From 2009 to 2010, he was a consultant to the boards of companies including ING Group NV and ASM International NV. Before that, he was CEO of NXP Semiconductors (a Philips spinoff) from 2004 to 2009.

Andreas von Planta

Mr. Andreas von Planta, Ph.D., has been Non-Executive Independent Director at Novartis Inc. since February 28, 2006. He is Chairman of the Governance, Nomination and Corporate Responsibilities Committee. He is also Member of the Risk Committee and the Audit and Compliance Committee. Mr. von Planta provides counsel to the law firm Lenz & Staehelin AG, where he was a partner from 1988 through 2017. He is a board member of Helvetia Holding AG in Switzerland, and also serves on the boards of various Swiss subsidiaries of foreign companies and other non-listed Swiss companies, including Burberry (Suisse) SA, Lenz & Staehelin, A.P. Moller Finance SA, HSBC Private Bank (Suisse) SA, Socotab Frana SA and Raymond Weil SA. Additionally, he is chairman of the regulatory board of the SIX Swiss Exchange AG. Mr. von Planta holds a doctorate in law from the University of Basel in Switzerland, and a Master of Laws from Columbia Law School in the United States. He passed his bar examinations in Basel in 1982, and specializes in corporate law, corporate governance, corporate finance, company reorganizations, and mergers and acquisitions. He previously served as chairman of Clinique Generale-Beaulieu SA from 2011 to 2016, and as a director there from 2008 to 2016. Additionally, he was chairman of Swiss National Insurance Company Ltd. (Nationale Suisse) from 2011 to 2015, a director at Nationale Suisse from 1997 to 2015, and a director at Holcim Ltd. from 2003 to 2014.

William Winters

Mr. William Thomas (Bill) Winters, CBE, has been Non-Executive Independent Director of Novartis Inc. since 2013. He is Member of the Compensation Committee. Mr. Winters is CEO and a board member of Standard Chartered, based in London. He also serves on the board of Colgate University in the United States, and on the boards of the International Rescue Committee and the Print Room theater in the United Kingdom. Mr. Winters received his bachelor’s degree from Colgate University and his Master of Business Administration from the Wharton School of the University of Pennsylvania. From 2011 to 2015, he was chairman and CEO of Renshaw Bay, an alternative asset management firm. Prior to that, he was co-CEO of JPMorgan’s investment bank from 2003 to 2010. He joined JPMorgan in 1983 and has held management roles across several market areas and in corporate finance. Additionally, he was a commissioner on the UK Independent Commission on Banking in 2010 and 2011, and was awarded the title of Commander of the Order of the British Empire in 2013.

Samir Shah